NASDAQ
14.11.25 | 21:59
20,070 US-Dollar
+1,24 % +0,245
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.10. | Arcus Biosciences stock falls after pricing $250 million public offering | 3 | Investing.com | ||
| 31.10. | Arcus Biosciences prices $250M offering | 2 | Seeking Alpha | ||
| 31.10. | Arcus Biosciences prices $250 million public offering at $18.25 per share | 2 | Investing.com | ||
| 30.10. | Hedge Fund and Insider Trading News: Paul Tudor Jones, Berkshire Hathaway, Soros Fund Management, Citadel Investment Group, LMR Partners, Iridium Communications Inc (IRDM), Arcus Biosciences Inc (RCUS), and More | 9 | Insider Monkey | ||
| 30.10. | Arcus Biosciences launches public offering of common stock | 1 | Investing.com | ||
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 29.10. | Analyst Expectations For Arcus Biosciences' Future | 2 | Benzinga.com | ||
| 28.10. | Arcus Biosciences: EPS übertrifft Schätzungen um 0,01 $ - Umsatz besser als erwartet | 2 | Investing.com Deutsch | ||
| 28.10. | Arcus Biosciences GAAP EPS of -$1.27 beats by $0.06, revenue of $26M beats by $5.75M | 1 | Seeking Alpha | ||
| 28.10. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 28.10. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.10. | Arcus Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.10. | Arcus Biosciences stock rises after strong gastric cancer survival data | 1 | Investing.com | ||
| 13.10. | Arcus Biosciences-Aktie steigt nach starken Überlebensdaten bei Magenkrebs | 1 | Investing.com Deutsch | ||
| 13.10. | Arcus Biosciences rises on results from domvanalimab cancer study | 1 | Seeking Alpha | ||
| 13.10. | Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months | 24 | Benzinga.com | ||
| 13.10. | Arcus Biosciences to present promising gastric cancer survival data | 1 | Investing.com | ||
| 07.10. | Truist Securities raises Arcus Biosciences stock price target on casdatifan potential | 1 | Investing.com | ||
| 07.10. | Casdatifan-Potenzial: Truist Securities hebt Kursziel für Arcus Biosciences an | 1 | Investing.com Deutsch | ||
| 07.10. | How Arcus Biosciences Aims To Take On Merck In Cancer Treatment | 9 | Investor's Business Daily | ||
| 06.10. | Why Is Arcus Biosciences Stock Trading Higher On Monday? | 1 | Benzinga.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 34,000 | +1,01 % | Novo Nordisk, Eli Lilly oder Viking Therapeutics: Wer gewinnt den Dreikampf? | Der Markt für Adipositas-Medikamente boomt - und die Konkurrenz zwischen den Schwergewichten Novo Nordisk und Eli Lilly prägt das Geschehen. Doch während sich die Giganten duellieren, könnte das viel... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,452 | -0,40 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| XOMA ROYALTY | 28,000 | 0,00 % | XOMA Royalty Corporation: XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements | Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,110 | +1,50 % | Why Rox Resources, Telix, TPG Telecom, and Xero shares are dropping today | ||
| BEAM THERAPEUTICS | 21,740 | +0,37 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,613 | -0,27 % | Rocket Pharmaceuticals, Inc. Q3 Loss Decreases, Beats Estimates | ||
| OUTLOOK THERAPEUTICS | 1,359 | +1,49 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD | Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 3,740 | -0,53 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results | Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024
BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia... ► Artikel lesen | |
| ROIVANT SCIENCES | 17,640 | +1,00 % | Guggenheim raises Roivant Sciences stock price target to $25 on pipeline progress | ||
| CARTESIAN THERAPEUTICS | 6,350 | -0,78 % | BTIG hebt Kursziel für Cartesian Therapeutics nach Studienerfolg auf 44 US-Dollar an | ||
| ANNOVIS BIO | 1,932 | -5,06 % | Annovis Bio, Inc. - 10-Q, Quarterly Report | ||
| ADVERUM BIOTECHNOLOGIES | 3,700 | 0,00 % | Eli Lilly To Acquire Adverum Biotechnologies In Deal Worth Up To $12.47 Per Share | INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) on Friday said it has agreed to acquire Adverum Biotechnologies, Inc. (ADVM) in a transaction valued at up to $12.47 per share.Under the... ► Artikel lesen | |
| REIN THERAPEUTICS | 1,140 | +5,56 % | Rein Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| QUINCE THERAPEUTICS | 1,680 | +1,20 % | Quince Therapeutics GAAP EPS of -$0.25 misses by $0.04 | ||
| NEUPHORIA THERAPEUTICS | 4,790 | +0,84 % | Neuphoria Therapeutics, Inc.: Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value | Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fund LP No Stockholder Action Required at This Time BURLINGTON, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen |
ARCUS BIOSCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,245 (+1,24 %) liegt der Kurs bei 20,070 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.